69 results about "Immunologic disease" patented technology

The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.

Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease.

The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and/or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.

The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.

The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I):

[wherein, especially, R¹ is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R² is methyl; R³ is a hydrogen atom; and R⁴ is a group: —CONR⁵R⁶ (in which any one of R⁵ and R⁶ is a hydrogen atom)].

The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly T_H17 and T_H1 T cell development, can be modulated by delivery of microRNA-155 (miR-155) or antisense miR-155 to target CD4+ cells or precursor cells. In some embodiments, antisense miR-155 is used to reduce tissue specific autoimmune inflalmmation and to treat autoimmune disease. In addition, miR155 and antisense miR-155 can be used to modulate expression of cytokines from dendritic cells.

The invention discloses a novel isoflavones compound as shown by a formula I. The results of animal experiments show that the isoflavones compound can significantly inhibit the proliferation of T cells and B cells, and can be used for preparing immunosuppressants or medicaments for treating immunologic diseases. The SI values (IC50/CC50) of the isoflavones compound are high, so the toxic side effects of the isoflavones compound are small, and the treatment interval of the isoflavones compound is wide. The isoflavones compound is obtained by extracting and separating clovershrubs, and the preparation method is simple and convenient.

The invention relates to a kit for detecting antinuclear antibody spectrum related to AIDs. The kit comprises a membrane strip, enzyme-labeled liquid, a substrate and concentrating and washing incubation liquid, wherein the membrane strip is composed of a carrier piece and an antigen band, a critical quality control band and a functional quality control line which are sequentially fixed on the carrier piece. The antigen band is composed of at least two of dsDNA, nucleosomes, SmD1, ribosome P0proteins, histones, U1snRNP, Ro/SS-A(52KD), Ro/SS-A(60KD), La/SS-B, Sc1-70, CENP-B, Jo-1, AMA-M2, PM-Sc1, PCNA, Mi-2 and Ku through independent marking to a nitrocellulose membrane or a nylon membrane. The kit is provided with the ingenious critical quality control band, one critical quality control band can play a role in interpreting two or even more detection bands (antigen bands), and result determination is simpler and more reliable.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.

The present invention provides methods of treating multiple sclerosis, type 1 diabetes mellitus and other autoimmune diseases by administering a soluble immune response suppressor (SIRS) peptide or a variant thereof to an individual having such disease. The SIRS peptide or variant reduces the severity of or frequency of relapse of multiple sclerosis and reduces the inflammation associated with multiple sclerosis and other autoimmune diseases.

The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.

The invention belongs to the field of chemical medicines, and in particular relates to 5-benzylidene-2,4-thiazolidinedione derivatives and a preparation method and application thereof. Aiming at solving the first technical problem, the invention provides a new series of 5-benzylidene-2,4-thiazolidinedione derivatives shown in a formula I, which has he function of treating immunologic diseases.

The invention relates to means and methods for determining whether a subject is at high or low risk of autoimmune disease progression by determining the CD8 or CD4 cell subtype of the subject. Autoimmune diseases of particular interest include vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The invention also relates to means and methods for determining the CD8 or CD4 cell subtype of a subject, e.g. for predicting responses to infection, vaccination and/or transplantation.

The invention discloses a coumaronochromones compound as shown by a formula 1. Pharmacological experiments show that the coumaronochromones compound has significant inhibitory action on the proliferation of B lymphocytes and T lymphocytes, and can be used for preparing immunosuppressive agents or medicaments for treating various immunologic diseases such as rheumatoid arthritis, lupus erythematosus and the like, and the medicaments for treating B cell type chronic lymphocytic leukemia. The invention also provides a preparation method.

A method of providing a reproducible and clinically relevant disease activity measurement for a group of immunologic disorders that share features of a T “helper” 1 (Th1) immune activation phenotype is disclosed. Th1 responses are characterized by the release of a set of pro-inflammatory substances by white blood cells (WBC) By evaluating the ex vivo activation response of whole blood in terms of the extent of release of Th1 produced pro-inflammatory substances in blood (i.e., WBC activity) following activation with a Th1-associated stimulant, the level of, e.g., disease activity or immunosuppression in a specific individual can be determined. The method of the invention provides a disease activity marker for a wide variety of Th1 inflammatory responses, including Crohn's Disease, psoriasis, rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), multiple sclerosis and solid organ transplant rejection.

The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.

The present invention is related to the haplotypes of human Transforming Growth Factor Beta1 (TGFβ1) and prediction of susceptibility for immunological disorders. More particularly the present study is the first study in any population, identifying novel protective and risk haplotypes of the TGFβ1 gene The present invention also relates to allelic variants of the human Transforming Growth Factor Beta1 (TGFβ1) gene. The said invention also provides primers and methods suitable for the detection of these haplotypes and allelic variants for the prediction of an individual's disease susceptibility, and /or the genetic analysis of the TGFβ1 gene for immunological disorders, particularly asthma. A vital aspect of the present study provides a method for predicting susceptibility of individuals to immunological disorders, particularly asthma.

The invention discloses medicinal application of A type proanthocyanidin trimer polyphenol. The medicinal application is that the A type proanthocyanidin trimer polyphenol is taken as one of active compositions or the only one active composition to prepare medicine preparations for treating immunologic diseases. Experiments show that the half cell lethal concentration of the A type proanthocyanidin trimer polyphenol is larger than 50 mu g/mL, and the A type proanthocyanidin trimer polyphenol has inhibiting effect on propagation of lymphocyte induced by mitogen ConA and secretion of cytokines IL-6 and IFN-gamma important for immunoloregulation and inflammation reactions, is expected to be taken as one of active compositions or the only one active composition for preparing medicine preparations for treating immunologic diseases, especially is expected to be taken as one of active compositions or the only one active composition for preparing medicine preparations for treating rheumatoid arthritis, and has medicinal value.

The present invention provides methods for generating mucosal tissue homing immunosuppressive T-cells comprising treating naïve T-cells with retinoids and/or retinoid agonists. Methods are also provided for treating a mammal having an inflammatory or immunological disease by administering a therapeutically effective dose of retinoids and/or retinoid agonists. Additional methods are also provided for boosting the immune system of a mammal by inhibiting the generation of immunosuppressive T-cells by administering a therapeutically effective dose of a retinoid receptor antagonist to the mammal.